Colossal editing tech will be applicable to human healthcare (spun out/licensed)

Colossal editing tech will be applicable to human healthcare (spun out/licensed) | I would feel comfortable that that technology could be applied to human healthcare. We're not going to do it. We'd spin it out or license it

I would feel comfortable that that technology could be applied to human healthcare. We're not going to do it. We'd spin it out or license it

Beneficiaries (19)

Adverse (4)

{
  "nia": false,
  "url": "https://www.youtube.com/watch?v=Goa6c6Qz__I",
  "mode": "PREDICTION",
  "role": "Guest-CEO",
  "caveats": "Colossal won't do it themselves",
  "context": "very precise uh to the point that um I would feel comfortable that that technology could be applied to human healthcare. We're not going to do it. We'd spin it out or license it",
  "verbatim": "I would feel comfortable that that technology could be applied to human healthcare. We're not going to do it. We'd spin it out or license it",
  "conv_cues": "would feel comfortable; could be applied",
  "direction": "HAPPEN",
  "timeframe": "Future",
  "conv_level": "MEDIUM",
  "milestones": [
    {
      "kind": "quartile_checkpoint",
      "label": "Q1 window check-in (25%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -9,
      "source_id": null,
      "expected_date": "2027-01-22",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "Form Bio (Colossal spinoff) closes growth-round funding for human-therapeutics applications",
      "source": "deep_research_enriched",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -8,
      "source_id": null,
      "confidence": 0.55,
      "source_url": "https://research.contrary.com/company/colossal-biosciences",
      "expected_date": "2027-03-17",
      "research_origin": "deep_research",
      "expected_date_range": {
        "to": "2027-12-31",
        "from": "2026-06-01"
      },
      "measurement_criterion": "Form Bio announces Series B+ raise with public communications referencing human therapeutic / drug discovery applications"
    },
    {
      "kind": "llm_pre_event",
      "label": "Colossal launches dedicated human-health spinout entity with named CEO/board",
      "source": "llm_enriched",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -7,
      "source_id": null,
      "confidence": 0.5,
      "expected_date": "2027-06-16",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2028-06-30",
        "from": "2026-06-01"
      },
      "measurement_criterion": "Press release announcing legal entity formation with explicit human-therapeutic mission, named leadership, separate funding"
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q2 window check-in (50%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -6,
      "source_id": null,
      "expected_date": "2027-10-17",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "First peer-reviewed publication applying Colossal's multiplex-edit pipeline to human-disease model",
      "source": "llm_enriched",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -5,
      "source_id": null,
      "confidence": 0.55,
      "expected_date": "2028-01-01",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2028-12-31",
        "from": "2027-01-01"
      },
      "measurement_criterion": "Peer-reviewed paper with Colossal/Form Bio author affiliation showing multiplex CRISPR-edit pipeline applied to disease-relevant human cell line or organoid"
    },
    {
      "kind": "llm_pre_event",
      "label": "Colossal/spinout signs licensing deal with established biopharma for gene-editing platform",
      "source": "llm_enriched",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -4,
      "source_id": null,
      "confidence": 0.45,
      "expected_date": "2028-05-03",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2029-04-05",
        "from": "2027-06-01"
      },
      "measurement_criterion": "Public licensing agreement or partnership announcement with top-50 pharma listing upfront >=$25M payments or milestones"
    },
    {
      "kind": "llm_post_event",
      "label": "Colossal IPO or strategic exit unlocks separate human-therapeutics valuation",
      "source": "llm_enriched",
     
... (truncated)